Target Price | $601.80 |
Price | $496.87 |
Potential | 21.12% |
Number of Estimates | 31 |
31 Analysts have issued a price target Intuitive Surgical 2026 . The average Intuitive Surgical target price is $601.80. This is 21.12% higher than the current stock price. The highest price target is $708.75 42.64% , the lowest is $444.40 10.56% . | |
A rating was issued by 39 analysts: 26 Analysts recommend Intuitive Surgical to buy, 12 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Intuitive Surgical stock has an average upside potential 2026 of 21.12% . Most analysts recommend the Intuitive Surgical stock at Purchase. |
37 Analysts have issued a sales forecast Intuitive Surgical 2025 . The average Intuitive Surgical sales estimate is $10.0b . This is 9.02% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $10.4b 13.67% , the lowest is $9.4b 3.18% .
This results in the following potential growth metrics:
2024 | $8.4b | 17.24% |
---|---|---|
2025 | $10.0b | 19.37% |
2026 | $11.4b | 14.31% |
2027 | $13.1b | 14.66% |
2028 | $14.3b | 9.59% |
2029 | $16.1b | 12.73% |
2030 | $18.2b | 12.85% |
2031 | $19.0b | 4.54% |
2032 | $20.9b | 9.60% |
37 Intuitive Surgical Analysts have issued a net profit forecast 2025. The average Intuitive Surgical net profit estimate is $2.9b . This is 9.93% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $3.1b 18.78% , the lowest is $2.7b 2.24% .
This results in the following potential growth metrics and future Net Margins:
2024 | $2.3b | 29.18% |
---|---|---|
2025 | $2.9b | 23.42% |
2026 | $3.3b | 15.34% |
2027 | $3.9b | 17.39% |
2028 | $4.3b | 11.38% |
2029 | $5.2b | 19.35% |
2030 | $6.1b | 18.72% |
2031 | $6.5b | 5.76% |
2032 | $7.0b | 8.41% |
2024 | 27.81% | 10.18% |
---|---|---|
2025 | 28.75% | 3.39% |
2026 | 29.01% | 0.90% |
2027 | 29.70% | 2.38% |
2028 | 30.19% | 1.65% |
2029 | 31.96% | 5.86% |
2030 | 33.62% | 5.19% |
2031 | 34.02% | 1.19% |
2032 | 33.64% | 1.12% |
37 Analysts have issued a Intuitive Surgical forecast for earnings per share. The average Intuitive Surgical EPS is $8.00 . This is 11.58% higher than earnings per share in the financial year 2024. The highest EPS forecast is $8.64 20.50% , the lowest is $7.44 3.77% .
This results in the following potential growth metrics and future valuations:
2024 | $6.42 | 27.63% |
---|---|---|
2025 | $8.00 | 24.61% |
2026 | $9.22 | 15.25% |
2027 | $10.83 | 17.46% |
2028 | $12.06 | 11.36% |
2029 | $14.40 | 19.40% |
2030 | $17.09 | 18.68% |
2031 | $18.07 | 5.73% |
2032 | $19.59 | 8.41% |
Current | 69.30 | 9.08% |
---|---|---|
2025 | 62.13 | 10.34% |
2026 | 53.86 | 13.31% |
2027 | 45.88 | 14.82% |
2028 | 41.19 | 10.22% |
2029 | 34.52 | 16.19% |
2030 | 29.07 | 15.79% |
2031 | 27.49 | 5.44% |
2032 | 25.36 | 7.75% |
Based on analysts' sales estimates for 2025, the Intuitive Surgical stock is valued at an EV/Sales of 16.91 and an P/S ratio of 17.87 .
This results in the following potential growth metrics and future valuations:
Current | 18.43 | 7.99% |
---|---|---|
2025 | 16.91 | 8.25% |
2026 | 14.79 | 12.52% |
2027 | 12.90 | 12.79% |
2028 | 11.77 | 8.75% |
2029 | 10.44 | 11.29% |
2030 | 9.25 | 11.38% |
2031 | 8.85 | 4.34% |
2032 | 8.08 | 8.76% |
Current | 19.48 | 5.78% |
---|---|---|
2025 | 17.87 | 8.27% |
2026 | 15.63 | 12.52% |
2027 | 13.63 | 12.79% |
2028 | 12.44 | 8.75% |
2029 | 11.03 | 11.29% |
2030 | 9.78 | 11.38% |
2031 | 9.35 | 4.34% |
2032 | 8.53 | 8.76% |
Intuitive Surgical...
Analyst | Rating | Action | Date |
---|---|---|---|
Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Jul 23 2025 |
Truist Securities |
Buy
➜
Buy
|
Unchanged | Jul 23 2025 |
UBS |
Neutral
➜
Neutral
|
Unchanged | Jul 23 2025 |
BTIG |
Buy
➜
Buy
|
Unchanged | Jul 23 2025 |
RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jul 23 2025 |
Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Jul 23 2025 |
Evercore ISI Group |
In-Line
➜
In-Line
|
Unchanged | Jul 08 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Jul 23 2025 |
Unchanged
Truist Securities:
Buy
➜
Buy
|
Jul 23 2025 |
Unchanged
UBS:
Neutral
➜
Neutral
|
Jul 23 2025 |
Unchanged
BTIG:
Buy
➜
Buy
|
Jul 23 2025 |
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jul 23 2025 |
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Jul 23 2025 |
Unchanged
Evercore ISI Group:
In-Line
➜
In-Line
|
Jul 08 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.